CTMX vs OABI
CTMX: CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer. OABI: OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical and biotech partners.
Side-by-side fundamentals
| Metric | CTMX | OABI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.33 | $2.11 | |
| Market cap as of 2026-07-23 | $724M | $300M | |
| Net margin as of 2026-07-23 | -166.4% | -187.6% | CTMX higher |
| Gross margin as of 2026-07-23 | n/a | +98.9% | |
| Operating margin as of 2026-07-23 | -181.9% | -200.3% | CTMX higher |
| ROE as of 2026-07-23 | -36.6% | -20.3% | OABI higher |
| ROA as of 2026-07-23 | -28.0% | -18.1% | OABI higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -75.9% | +8.2% | OABI higher |
| Revenue CAGR (3y) SEC XBRL | +12.8% | -31.9% | CTMX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 2.16 | 0.44 | |
| 1-year return as of 2026-07-22 close | +43.7% | +5.6% | CTMX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.